# üìã Document Numbering Guide

## ‚úÖ Implemented: Hierarchical Numbering for All Documents

All generated documents now include proper hierarchical numbering according to ICH/FDA guidelines.

---

## 1Ô∏è‚É£ Investigator's Brochure (IB)

**Standard:** ICH E6 (R2) Section 7

### Structure:
```
1. TITLE PAGE
2. TABLE OF CONTENTS
3. SUMMARY
4. INTRODUCTION
5. PHYSICAL, CHEMICAL, AND PHARMACEUTICAL PROPERTIES AND FORMULATION
   5.1 Physical and Chemical Properties
   5.2 Pharmaceutical Formulation
6. NONCLINICAL STUDIES
   6.1 Nonclinical Pharmacology
       6.1.1 Primary Pharmacodynamics
       6.1.2 Secondary Pharmacodynamics
       6.1.3 Safety Pharmacology
   6.2 Pharmacokinetics and Product Metabolism
       6.2.1 Absorption
       6.2.2 Distribution
       6.2.3 Metabolism
       6.2.4 Excretion
   6.3 Toxicology
       6.3.1 Single-Dose Toxicity
       6.3.2 Repeat-Dose Toxicity
       6.3.3 Genotoxicity
       6.3.4 Carcinogenicity
       6.3.5 Reproductive and Developmental Toxicity
       6.3.6 Local Tolerance
7. EFFECTS IN HUMANS
   7.1 Pharmacokinetics and Product Metabolism in Humans
       7.1.1 Absorption
       7.1.2 Distribution
       7.1.3 Metabolism
       7.1.4 Excretion
       7.1.5 Drug-Drug Interactions
   7.2 Pharmacodynamics and Efficacy in Humans
       7.2.1 Mechanism of Action
       7.2.2 Dose-Response Relationships
       7.2.3 Clinical Efficacy
   7.3 Safety and Tolerability
       7.3.1 Adverse Events
       7.3.2 Serious Adverse Events
       7.3.3 Clinical Laboratory Findings
       7.3.4 Special Populations
8. SUMMARY OF DATA AND GUIDANCE FOR THE INVESTIGATOR
9. REFERENCES
```

### Markdown Format:
```markdown
## 6 NONCLINICAL STUDIES

### 6.1 Nonclinical Pharmacology

#### 6.1.1 Primary Pharmacodynamics
Content here...

#### 6.1.2 Secondary Pharmacodynamics
Content here...
```

---

## 2Ô∏è‚É£ Clinical Trial Protocol

**Standard:** ICH E6 (R2) Section 6

### Structure:
```
1. TITLE PAGE AND PROTOCOL SYNOPSIS
   1.1 Protocol Title
   1.2 Protocol Number
   1.3 Protocol Synopsis (Tabular Format)
2. TABLE OF CONTENTS
3. LIST OF ABBREVIATIONS
4. INTRODUCTION
   4.1 Background
   4.2 Rationale
   4.3 Risk-Benefit Assessment
5. STUDY OBJECTIVES AND ENDPOINTS
   5.1 Primary Objective
   5.2 Secondary Objectives
   5.3 Primary Endpoint
   5.4 Secondary Endpoints
   5.5 Exploratory Endpoints
6. STUDY DESIGN
   6.1 Overall Study Design and Plan
   6.2 Study Schema/Diagram
   6.3 Randomization and Blinding
   6.4 Study Duration
7. STUDY POPULATION
   7.1 Inclusion Criteria
   7.2 Exclusion Criteria
   7.3 Withdrawal Criteria
   7.4 Screen Failures and Re-screening
8. STUDY TREATMENTS
   8.1 Investigational Product
       8.1.1 Description
       8.1.2 Dosage and Administration
       8.1.3 Packaging and Labeling
   8.2 Concomitant Medications
       8.2.1 Permitted Medications
       8.2.2 Prohibited Medications
   8.3 Compliance Assessment
9. STUDY PROCEDURES AND ASSESSMENTS
   9.1 Schedule of Activities
   9.2 Screening Period
   9.3 Treatment Period
   9.4 Follow-up Period
   9.5 Efficacy Assessments
   9.6 Safety Assessments
       9.6.1 Physical Examinations
       9.6.2 Vital Signs
       9.6.3 Laboratory Assessments
       9.6.4 ECG
   9.7 Pharmacokinetic Assessments
10. SAFETY MONITORING
    10.1 Adverse Event Definitions
    10.2 Adverse Event Reporting
    10.3 Serious Adverse Event Reporting
    10.4 Data Safety Monitoring Board
    10.5 Stopping Rules
11. STATISTICAL CONSIDERATIONS
    11.1 Sample Size Determination
    11.2 Populations for Analysis
    11.3 Statistical Methods
        11.3.1 Primary Endpoint Analysis
        11.3.2 Secondary Endpoint Analysis
        11.3.3 Safety Analysis
    11.4 Interim Analysis
    11.5 Handling of Missing Data
12. QUALITY CONTROL AND QUALITY ASSURANCE
    12.1 Data Management
    12.2 Monitoring
    12.3 Audits
13. ETHICAL AND REGULATORY CONSIDERATIONS
    13.1 Ethical Conduct
    13.2 Informed Consent
    13.3 Confidentiality
    13.4 Protocol Amendments
14. STUDY ADMINISTRATION
    14.1 Investigators and Study Personnel
    14.2 Financing and Insurance
    14.3 Publication Policy
15. REFERENCES
16. APPENDICES
```

### Markdown Format:
```markdown
## 11 STATISTICAL CONSIDERATIONS

### 11.1 Sample Size Determination
Content here...

### 11.3 Statistical Methods

#### 11.3.1 Primary Endpoint Analysis
Content here...
```

---

## 3Ô∏è‚É£ Informed Consent Form (ICF)

**Standard:** FDA 21 CFR Part 50

### Structure:
```
1. TITLE PAGE
2. INTRODUCTION AND INVITATION TO PARTICIPATE
   2.1 Study Title
   2.2 Invitation Statement
   2.3 Voluntary Participation
3. WHY IS THIS STUDY BEING DONE?
   3.1 Purpose of the Study
   3.2 Why You Are Being Asked
   3.3 Number of Participants
4. WHAT WILL HAPPEN IF I TAKE PART IN THIS STUDY?
   4.1 Study Duration
   4.2 Study Visits and Procedures
       4.2.1 Screening Visit
       4.2.2 Treatment Visits
       4.2.3 Follow-up Visits
   4.3 Study Drug Information
       4.3.1 How to Take the Study Drug
       4.3.2 What to Avoid
5. WHAT ARE THE RISKS OF THIS STUDY?
   5.1 Known Risks of Study Drug
   5.2 Possible Risks
   5.3 Risks of Study Procedures
   5.4 Reproductive Risks
   5.5 Unknown Risks
6. ARE THERE BENEFITS TO TAKING PART IN THIS STUDY?
   6.1 Possible Benefits to You
   6.2 Benefits to Others
7. WHAT OTHER CHOICES DO I HAVE?
   7.1 Alternative Treatments
   7.2 Choosing Not to Participate
8. WILL MY INFORMATION BE KEPT CONFIDENTIAL?
   8.1 How Your Information Will Be Protected
   8.2 Who May See Your Information
   8.3 Certificate of Confidentiality
9. WHAT ARE THE COSTS?
   9.1 Costs to You
   9.2 Payment for Participation
   9.3 Insurance and Billing
10. WHAT IF I AM INJURED?
    10.1 Medical Care
    10.2 Compensation
11. WHAT ARE MY RIGHTS AS A PARTICIPANT?
    11.1 Voluntary Participation
    11.2 Right to Withdraw
    11.3 New Information
    11.4 Questions and Contacts
12. CONSENT SIGNATURES
    12.1 Participant Signature
    12.2 Person Obtaining Consent
    12.3 Legally Authorized Representative (if applicable)
```

### Markdown Format:
```markdown
## 4 WHAT WILL HAPPEN IF I TAKE PART IN THIS STUDY?

### 4.2 Study Visits and Procedures

#### 4.2.1 Screening Visit
You will come to the clinic for a screening visit...
```

---

## 4Ô∏è‚É£ Protocol Synopsis

**Standard:** ICH E3 Section 2

### Structure:
```
1. SYNOPSIS HEADER (TABULAR FORMAT)
   1.1 Protocol Title
   1.2 Protocol Number
   1.3 Study Phase
   1.4 Study Dates
   1.5 Sponsor
   1.6 Investigational Product
   1.7 Indication
2. STUDY OBJECTIVES
   2.1 Primary Objective
   2.2 Secondary Objectives
3. STUDY DESIGN
   3.1 Overall Design
   3.2 Study Schema
   3.3 Randomization and Blinding
   3.4 Study Duration
4. STUDY ENDPOINTS
   4.1 Primary Endpoint
   4.2 Secondary Endpoints
   4.3 Safety Endpoints
5. STUDY POPULATION
   5.1 Planned Number of Subjects
   5.2 Key Inclusion Criteria
   5.3 Key Exclusion Criteria
   5.4 Subject Disposition
   5.5 Demographics and Baseline Characteristics
6. STATISTICAL METHODS
   6.1 Sample Size Determination
   6.2 Analysis Populations
   6.3 Statistical Tests
   6.4 Significance Level
7. EFFICACY RESULTS
   7.1 Primary Efficacy Analysis
   7.2 Secondary Efficacy Analyses
   7.3 Subgroup Analyses
8. SAFETY RESULTS
   8.1 Extent of Exposure
   8.2 Adverse Events
   8.3 Serious Adverse Events
   8.4 Deaths
   8.5 Laboratory Findings
   8.6 Vital Signs and Physical Examinations
9. PHARMACOKINETICS (if applicable)
   9.1 PK Parameters
   9.2 PK/PD Relationships
10. CONCLUSIONS
    10.1 Efficacy Conclusions
    10.2 Safety Conclusions
    10.3 Overall Benefit-Risk Assessment
```

### Markdown Format:
```markdown
## 7 EFFICACY RESULTS

### 7.1 Primary Efficacy Analysis
Content here...

### 7.2 Secondary Efficacy Analyses
Content here...
```

---

## üìù Formatting Rules

### Main Sections (Level 1):
```markdown
## [NUMBER] [TITLE IN CAPS]
```
Example: `## 5 STUDY OBJECTIVES AND ENDPOINTS`

### Subsections (Level 2):
```markdown
### [NUMBER] [Title in Title Case]
```
Example: `### 5.1 Primary Objective`

### Sub-subsections (Level 3):
```markdown
#### [NUMBER] [Title in Title Case]
```
Example: `#### 8.1.1 Description`

---

## ‚úÖ Benefits of Proper Numbering

### 1. Regulatory Compliance
- ‚úÖ Meets ICH E6 requirements
- ‚úÖ Meets FDA 21 CFR requirements
- ‚úÖ Meets ICH E3 requirements
- ‚úÖ Ready for submission

### 2. Professional Appearance
- ‚úÖ Industry-standard format
- ‚úÖ Easy to read
- ‚úÖ Consistent structure
- ‚úÖ Professional presentation

### 3. Easy Navigation
- ‚úÖ Quick section lookup
- ‚úÖ Clear hierarchy
- ‚úÖ Easy cross-referencing
- ‚úÖ Table of Contents friendly

### 4. Audit Trail
- ‚úÖ Clear section identification
- ‚úÖ Easy version comparison
- ‚úÖ Trackable changes
- ‚úÖ Compliance documentation

### 5. Collaboration
- ‚úÖ Easy to reference in comments
- ‚úÖ Clear communication
- ‚úÖ Consistent across teams
- ‚úÖ Reduced ambiguity

---

## üöÄ Implementation Status

‚úÖ **IB (Investigator's Brochure)** - ICH E6 Section 7 compliant

‚úÖ **Protocol** - ICH E6 Section 6 compliant

‚úÖ **ICF (Informed Consent Form)** - FDA 21 CFR Part 50 compliant

‚úÖ **Synopsis** - ICH E3 Section 2 compliant

---

## üìñ References

1. **ICH E6 (R2)** - Good Clinical Practice
   - Section 6: Clinical Trial Protocol and Protocol Amendment(s)
   - Section 7: Investigator's Brochure

2. **FDA 21 CFR Part 50** - Protection of Human Subjects
   - Subpart B: Informed Consent of Human Subjects

3. **ICH E3** - Structure and Content of Clinical Study Reports
   - Section 2: Synopsis

---

## üéØ Next Steps

When generating new documents:
1. ‚úÖ Numbering is automatic
2. ‚úÖ Structure is compliant
3. ‚úÖ Format is correct
4. ‚úÖ Ready for review

**No manual numbering needed!** The AI generates properly numbered documents automatically.

---

**Last Updated:** November 10, 2025
**Status:** ‚úÖ Deployed to Production
**Edge Function:** generate-document (version 3)
